ClinicalTrials.gg
CompletedNCT02344017DUALIDESUpdated Dec 19, 2019

Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 1/2 interventional study of ODM-204 and Prednisone in Prostate Cancer, sponsored by Orion Corporation, Orion Pharma. Completed at 4 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-19.

Sponsored by Orion Corporation, Orion Pharma · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 126 studies in Prostatic Neoplasms with a site in Finland — 19 open to participants now, 37 under way, 14 of them phase 3. Prostatic Neoplasms · Finland.

Enrollment
109th of 113
23 · median 320
Started
2015
with 8 others
Phase 1/2
7 of 126
none open now
Registered
63rd of 126
by date
Lead sponsor
4 of 126
Orion Corporation, Orion Pharma

Among the 126 studies in Prostatic Neoplasms with a site in Finland, this one is the 109th largest by enrollment of the 113 interventional ones that give a count, is one of 9 that started in 2015, is one of 7 in phase 1/2, and was the 63rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

19 of the 126 studies in Prostatic Neoplasms with a site in Finland are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Prostatic Neoplasms with a site in Finland, or all of them as a file.
02

Study summary

The purpose of this first-in-man study is to evaluate safety, tolerability and pharmacokinetics of ODM-204 in patients with metastatic castration-resistant prostate cancer.

Read the detailed description

The safety profile of ODM-204 will be explored together with the pharmacokinetics, pharmacodynamics and tumour response to treatment with ODM-204 to recommend the dosing regimen for further clinical studies. The pharmacokinetic properties of ODM-204 will be evaluated after single and multiple dose administrations at different dose levels.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written (IC) obtained.
  • Male aged ≥ 18 years.
  • or cytologically confirmed adenocarcinoma of prostate.
  • Ongoing GnRH agonist or antagonist therapy, or after bilateral orchiectomy.
  • Progressive disease
  • Adequate bone marrow, hepatic, and renal function
  • Acceptable and regular bowel movements without any GI disorder or procedure which may interfere with absorption of study treatment
  • Ability to swallow study treatments

Exclusion criteria

Exclusion Criteria:

  • History of pituitary or adrenal dysfunction.
  • Known .
  • Active infection or other medical condition that would make prednisone () .
  • Uncontrolled hypertension
  • heart disease
  • Prolonged
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    ODM-204 Phase I dose escalation

    Dose escalation

    Drug: ODM-204 · Drug: Prednisone

  • Experimental
    ODM-204 Phase II dose expansion

    Drug: ODM-204 · Drug: Prednisone

Interventions

  • DrugODM-204

    co-administered with prednisone, orally daily

  • ODM-204 is co-administered with oral prednisone

06

What researchers measure

Primary outcomes

  1. Safety and tolerability assessed by incidence of adverse events

    Time frame: Until disease progression, an expected average of 6 months

  2. Safety and tolerability assessed by vitals signs and 12-lead ECG

    Time frame: Until disease progression, an expected average of 6 months

  3. Safety and tolerability assessed by laboratory assessments

    Time frame: Until disease progression, an expected average of 6 months

Secondary outcomes

  1. Pharmacokinetic profile assessed by plasma peak concentration (Cmax)

    Time frame: 0 - week 12

  2. Pharmacokinetic profile assessed by area under the concentration-time curve (AUC)

    Time frame: 0 - week 12

  3. Pharmacokinetic profile assessed by time to reach peak concentration (tmax)

    Time frame: 0 - week 12

  4. Preliminary antitumour activity assessed by prostate specific antigen (PSA) response

    Time frame: Until disease progression, an expected average of 6 months

  5. Preliminary antitumour activity assessed by response in soft and bone tissues

    Time frame: Until disease progression, an expected average of 6 months

  6. Pharmacodynamic profile assessed by hormone and circulating tumour cell measurements

    Time frame: 0 - week 12

07

Study locations

4 sites
  • Helsinki University Central Hospital
    Helsinki, Finland
  • Institut Gustave Roussy
    Villejuif, France
  • P. Stradins Clinical University Hospital
    Riga, Latvia
  • Velindre Cancer Centre
    Cardiff, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Jan 2019 and a completion of Jan 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2014
First posted
Jan 22, 2015
Start
Feb 2015
Primary completionActual
Jan 2019
CompletionActual
Jan 2019
Last update
Dec 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02344017
Responsible party
Sponsor
First posted
Jan 22, 2015
Start date
Feb 2015
Primary completion
Jan 2019
Completion
Jan 2019
Last update
Dec 19, 2019

Study contacts

Karim Fizazi
principal investigator · Gustave Roussy, Cancer Campus, Grand Paris

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion